Abstract Aim: The present study aims to associate erythrocyte aggregation with plasma lipid concentration. Materials & Methods: Ninety-nine participants were divided into two groups: normolipidemic and dyslipidemic. Lipid parameters were measured from serum and erythrocyte aggregation parameters: critical stress and critical time were measured from whole blood. Data were analyzed using IBS SPSS statistics software. Results: Erythrocyte aggregation was higher in the dyslipidemic group when compared with the normolipidemic group. Erythrocyte aggregation was associated with the abnormalities in lipid parameters, with the association of HDL-cholesterol and triglyceride being stronger than that of LDL-cholesterol and total cholesterol. Conclusion: The strong association of triglyceride and HDL-cholesterol with erythrocyte aggregation emphasizes the role of these lipids in the cardiovascular system.
{"title":"The association of dyslipidemia with erythrocyte aggregation","authors":"P. Gyawali, R. Richards, P. Bwititi, E. Nwose","doi":"10.2217/clp.15.3","DOIUrl":"https://doi.org/10.2217/clp.15.3","url":null,"abstract":"Abstract Aim: The present study aims to associate erythrocyte aggregation with plasma lipid concentration. Materials & Methods: Ninety-nine participants were divided into two groups: normolipidemic and dyslipidemic. Lipid parameters were measured from serum and erythrocyte aggregation parameters: critical stress and critical time were measured from whole blood. Data were analyzed using IBS SPSS statistics software. Results: Erythrocyte aggregation was higher in the dyslipidemic group when compared with the normolipidemic group. Erythrocyte aggregation was associated with the abnormalities in lipid parameters, with the association of HDL-cholesterol and triglyceride being stronger than that of LDL-cholesterol and total cholesterol. Conclusion: The strong association of triglyceride and HDL-cholesterol with erythrocyte aggregation emphasizes the role of these lipids in the cardiovascular system.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"1 1","pages":"129 - 135"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79885705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract “The claim that HPS2 THRIVE proved that niacin induced more adverse effects than the statin arm of the study is not supported by the data.”
“HPS2 THRIVE证明烟酸比他汀类药物引起的不良反应更多的说法没有数据支持。”
{"title":"The appropriate clinical use of niacin in the treatment of dyslipidemia","authors":"M. Houston, Mimi Guarneri, J. Kahn","doi":"10.2217/clp.14.60","DOIUrl":"https://doi.org/10.2217/clp.14.60","url":null,"abstract":"Abstract “The claim that HPS2 THRIVE proved that niacin induced more adverse effects than the statin arm of the study is not supported by the data.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"129 1","pages":"17 - 22"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81336491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie Hennebelle, E. Harbeby, S. Tremblay, R. Chouinard‐Watkins, F. Pifferi, M. Plourde, P. Guesnet, S. Cunnane
Abstract DHA, an omega-3 fatty acid, is an important constituent of brain membranes and has a key role in brain development and function. This review aims to highlight recent research on DHA’s role during age-related cognitive decline and Alzheimer’s disease. Animal and in vitro studies have provided some interesting mechanistic leads, especially on brain glucose metabolism, that may be involved in neuroprotection by DHA. However, results from human studies are more mitigated, perhaps due to changing DHA metabolism during aging. Recent innovative tools such as 13C-DHA for metabolic studies and 11C-DHA for PET provide interesting opportunities to study factors that affect DHA homeostasis during aging and to better understand whether and how to use DHA to delay or treat Alzheimer’s disease.
{"title":"Challenges to determining whether DHA can protect against age-related cognitive decline","authors":"Marie Hennebelle, E. Harbeby, S. Tremblay, R. Chouinard‐Watkins, F. Pifferi, M. Plourde, P. Guesnet, S. Cunnane","doi":"10.2217/clp.14.61","DOIUrl":"https://doi.org/10.2217/clp.14.61","url":null,"abstract":"Abstract DHA, an omega-3 fatty acid, is an important constituent of brain membranes and has a key role in brain development and function. This review aims to highlight recent research on DHA’s role during age-related cognitive decline and Alzheimer’s disease. Animal and in vitro studies have provided some interesting mechanistic leads, especially on brain glucose metabolism, that may be involved in neuroprotection by DHA. However, results from human studies are more mitigated, perhaps due to changing DHA metabolism during aging. Recent innovative tools such as 13C-DHA for metabolic studies and 11C-DHA for PET provide interesting opportunities to study factors that affect DHA homeostasis during aging and to better understand whether and how to use DHA to delay or treat Alzheimer’s disease.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"31 1","pages":"102 - 91"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87034600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract “ The key to this strategy will be to identify ways of inducing white adipose tissue browning and applying this knowledge clinically as a means of treating and preventing obesity.”
{"title":"Understanding adipocyte types and adipose tissue dynamics for obesity management","authors":"P. Zahradka, Carla G. Taylor","doi":"10.2217/clp.14.58","DOIUrl":"https://doi.org/10.2217/clp.14.58","url":null,"abstract":"Abstract “ The key to this strategy will be to identify ways of inducing white adipose tissue browning and applying this knowledge clinically as a means of treating and preventing obesity.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"18 1","pages":"23 - 26"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75486659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract “overall, the evidence from prospective cohort studies shows that milk/dairy consumption does not increase cardiovascular disease risk.”
摘要:“总的来说，前瞻性队列研究的证据表明，牛奶/乳制品的消费不会增加心血管疾病的风险。”
{"title":"Public health implications of milk fats: the current evidence base and future directions","authors":"O. Markey, D. Hobbs, D. Givens","doi":"10.2217/clp.14.66","DOIUrl":"https://doi.org/10.2217/clp.14.66","url":null,"abstract":"Abstract “overall, the evidence from prospective cohort studies shows that milk/dairy consumption does not increase cardiovascular disease risk.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"20 1","pages":"5 - 8"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74116744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract “preliminary clinical trials suggest that Krill oil is an alternative source of polyunsaturated fatty acids with peculiar effects in humans.”
摘要“初步临床试验表明，磷虾油是多不饱和脂肪酸的一种替代来源，对人体有特殊作用。”
{"title":"Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability","authors":"A. Cicero, A. Colletti","doi":"10.2217/clp.14.67","DOIUrl":"https://doi.org/10.2217/clp.14.67","url":null,"abstract":"Abstract “preliminary clinical trials suggest that Krill oil is an alternative source of polyunsaturated fatty acids with peculiar effects in humans.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"73 1","pages":"1 - 4"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74394160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James Underberg, MD, is a clinical assistant professor of medicine and clinical lipidologist at New York University Medical School and the NYU Center for Prevention of Cardiovascular Disease. He is the Director of the Lipid Clinic at Bellevue Hospital in New York City. He is also a member of the board of directors of the National Lipid Association, and serves on the scientific advisory board of the FH Foundation. He serves on the editorial board of the Journal of Clinical Lipidology. Dr. Underberg's clinical interests focus on the clinical management of patients with lipids and lipoprotein disorders, hypertension management and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology.
医学博士James Underberg是纽约大学医学院和纽约大学心血管疾病预防中心的临床医学助理教授和临床血脂学家。他是纽约市贝尔维尤医院脂质诊所的主任。他也是the National脂质协会的董事会成员，并在FH Foundation的科学顾问委员会任职。他是Journal of Clinical Lipidology的编辑委员会成员。Underberg博士的临床兴趣集中在脂质和脂蛋白紊乱患者的临床管理，高血压管理和心血管疾病预防。他在这些领域保持着积极的临床研究计划，并在临床脂质学领域撰写了许多文章和书籍章节。
{"title":"The National Lipid Association’s new recommendations for patient-centered management of cholesterol","authors":"James A. Underberg","doi":"10.2217/CLP.14.68","DOIUrl":"https://doi.org/10.2217/CLP.14.68","url":null,"abstract":"James Underberg, MD, is a clinical assistant professor of medicine and clinical lipidologist at New York University Medical School and the NYU Center for Prevention of Cardiovascular Disease. He is the Director of the Lipid Clinic at Bellevue Hospital in New York City. He is also a member of the board of directors of the National Lipid Association, and serves on the scientific advisory board of the FH Foundation. He serves on the editorial board of the Journal of Clinical Lipidology. Dr. Underberg's clinical interests focus on the clinical management of patients with lipids and lipoprotein disorders, hypertension management and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"94 1","pages":"13 - 15"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73287440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract More than 25 years of clinical trial data have established statins as first-line therapy for the prevention and treatment of atherosclerotic cardiovascular disease. With regard to low-density lipoprotein cholesterol, a wealth of evidence indicates that ‘lower is better,’ although recent guidelines from the American College of Cardiology and the American Heart Association take a different approach. A variety of approved and experimental lipid-lowering agents may be used as supplements or alternatives to statin therapy in patient subgroups, including those with familial hypercholesterolemia, mixed dyslipidemia or statin intolerance. Strategies to achieve further reductions in low-density lipoprotein cholesterol, target high-density lipoprotein cholesterol and triglycerides or reduce inflammation may help address residual cardiovascular risk, although early lifestyle interventions are crucial to prevention strategies.
超过25年的临床试验数据表明，他汀类药物是预防和治疗动脉粥样硬化性心血管疾病的一线药物。关于低密度脂蛋白胆固醇，大量证据表明“越低越好”，尽管美国心脏病学会(American College of Cardiology)和美国心脏协会(American Heart Association)最近发布的指南采用了不同的方法。在患者亚组中，包括家族性高胆固醇血症、混合性血脂异常或他汀类药物不耐受的患者，可使用多种经批准的实验性降脂药作为他汀类药物治疗的补充或替代。尽管早期生活方式干预对预防策略至关重要，但进一步降低低密度脂蛋白胆固醇、靶向高密度脂蛋白胆固醇和甘油三酯或减少炎症的策略可能有助于解决残留的心血管风险。
{"title":"Twenty-five years of statins: where do we go from here?","authors":"A. Gotto, Jennifer E. Moon","doi":"10.2217/clp.14.62","DOIUrl":"https://doi.org/10.2217/clp.14.62","url":null,"abstract":"Abstract More than 25 years of clinical trial data have established statins as first-line therapy for the prevention and treatment of atherosclerotic cardiovascular disease. With regard to low-density lipoprotein cholesterol, a wealth of evidence indicates that ‘lower is better,’ although recent guidelines from the American College of Cardiology and the American Heart Association take a different approach. A variety of approved and experimental lipid-lowering agents may be used as supplements or alternatives to statin therapy in patient subgroups, including those with familial hypercholesterolemia, mixed dyslipidemia or statin intolerance. Strategies to achieve further reductions in low-density lipoprotein cholesterol, target high-density lipoprotein cholesterol and triglycerides or reduce inflammation may help address residual cardiovascular risk, although early lifestyle interventions are crucial to prevention strategies.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"23 1","pages":"33 - 45"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78531595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract “With mixed results in recent clinical trials and meta-analyses some doubt has been raised on the efficacy of omega-3 polyunsaturated fatty acidsfor management of cardiovascular disease.”
{"title":"Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?","authors":"N. Shaikh, P. Tappia","doi":"10.2217/clp.15.1","DOIUrl":"https://doi.org/10.2217/clp.15.1","url":null,"abstract":"Abstract “With mixed results in recent clinical trials and meta-analyses some doubt has been raised on the efficacy of omega-3 polyunsaturated fatty acidsfor management of cardiovascular disease.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"11 1","pages":"27 - 32"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89178045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Robert, Wai Hang Cheng, Arooj Hayat, Taylor Ward-Able, C. Wellington
Abstract The brain is the most lipid-rich organ in the body and contains 25% of the body’s total cholesterol content. ApoE is the major apolipoprotein expressed in the brain and genetic variations in apoE underlie much of the genetically determined risk of late-onset Alzheimer’s disease. Regulation of lipid homeostasis in the CNS is therefore of great interest for healthy brain aging. The brain’s lipid transport system is built around lipoprotein particles that are similar in size and presumed function to circulating HDL. It is increasingly appreciated that many comorbidities that increase Alzheimer’s disease risk include aspects of aberrant HDL-metabolism, yet how circulating HDL may impact brain health is not fully understood. As comprehending the similarities and differences between CNS and peripheral lipid metabolism may reveal important relationships between cardiovascular and neurological diseases, here we review the fundamental properties of HDL metabolism in both peripheral and CNS compartments.
{"title":"High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism","authors":"J. Robert, Wai Hang Cheng, Arooj Hayat, Taylor Ward-Able, C. Wellington","doi":"10.2217/clp.14.64","DOIUrl":"https://doi.org/10.2217/clp.14.64","url":null,"abstract":"Abstract The brain is the most lipid-rich organ in the body and contains 25% of the body’s total cholesterol content. ApoE is the major apolipoprotein expressed in the brain and genetic variations in apoE underlie much of the genetically determined risk of late-onset Alzheimer’s disease. Regulation of lipid homeostasis in the CNS is therefore of great interest for healthy brain aging. The brain’s lipid transport system is built around lipoprotein particles that are similar in size and presumed function to circulating HDL. It is increasingly appreciated that many comorbidities that increase Alzheimer’s disease risk include aspects of aberrant HDL-metabolism, yet how circulating HDL may impact brain health is not fully understood. As comprehending the similarities and differences between CNS and peripheral lipid metabolism may reveal important relationships between cardiovascular and neurological diseases, here we review the fundamental properties of HDL metabolism in both peripheral and CNS compartments.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"5 1","pages":"69 - 81"},"PeriodicalIF":0.0,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88214430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：